168 related articles for article (PubMed ID: 27206431)
1. TERT Genetic Mutations as Prognostic Marker in Glioma.
Geng P; Zhao X; Ou J; Li J; Sa R; Liang H
Mol Neurobiol; 2017 Jul; 54(5):3665-3669. PubMed ID: 27206431
[TBL] [Abstract][Full Text] [Related]
2. Association of Telomerase Reverse Transcriptase Promoter Mutations with the Prognosis of Glioma Patients: a Meta-Analysis.
Wang X; Li X; Xu F; Zhang Y; Liu H; Tao Y
Mol Neurobiol; 2016 May; 53(4):2726-32. PubMed ID: 26351078
[TBL] [Abstract][Full Text] [Related]
3. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.
Vuong HG; Altibi AMA; Duong UNP; Ngo HTT; Pham TQ; Chan AK; Park CK; Fung KM; Hassell L
Crit Rev Oncol Hematol; 2017 Dec; 120():1-9. PubMed ID: 29198322
[TBL] [Abstract][Full Text] [Related]
4. TERT mutation in glioma: Frequency, prognosis and risk.
Yuan Y; Qi C; Maling G; Xiang W; Yanhui L; Ruofei L; Yunhe M; Jiewen L; Qing M
J Clin Neurosci; 2016 Apr; 26():57-62. PubMed ID: 26765760
[TBL] [Abstract][Full Text] [Related]
5. TERT promoter mutations lead to high transcriptional activity under hypoxia and temozolomide treatment and predict poor prognosis in gliomas.
Chen C; Han S; Meng L; Li Z; Zhang X; Wu A
PLoS One; 2014; 9(6):e100297. PubMed ID: 24937153
[TBL] [Abstract][Full Text] [Related]
6. TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas.
Gao K; Li G; Qu Y; Wang M; Cui B; Ji M; Shi B; Hou P
Oncotarget; 2016 Feb; 7(8):8712-25. PubMed ID: 26556853
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of genetic biomarkers in isocitrate dehydrogenase-wild-type lower-grade glioma: the need to further stratify this tumor entity - a meta-analysis.
Vuong HG; Tran TTK; Ngo HTT; Pham TQ; Nakazawa T; Fung KM; Hassell L; Katoh R; Kondo T
Eur J Neurol; 2019 Mar; 26(3):379-387. PubMed ID: 30298540
[TBL] [Abstract][Full Text] [Related]
8. Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.
Spiegl-Kreinecker S; Lötsch D; Ghanim B; Pirker C; Mohr T; Laaber M; Weis S; Olschowski A; Webersinke G; Pichler J; Berger W
Neuro Oncol; 2015 Sep; 17(9):1231-40. PubMed ID: 25681309
[TBL] [Abstract][Full Text] [Related]
9. Human TERT promoter mutations as a prognostic biomarker in glioma.
Powter B; Jeffreys SA; Sareen H; Cooper A; Brungs D; Po J; Roberts T; Koh ES; Scott KF; Sajinovic M; Vessey JY; de Souza P; Becker TM
J Cancer Res Clin Oncol; 2021 Apr; 147(4):1007-1017. PubMed ID: 33547950
[TBL] [Abstract][Full Text] [Related]
10. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
11. The TERT rs2736100 polymorphism increases cancer risk: A meta-analysis.
Li H; Xu Y; Mei H; Peng L; Li X; Tang J
Oncotarget; 2017 Jun; 8(24):38693-38705. PubMed ID: 28418878
[TBL] [Abstract][Full Text] [Related]
12. EZH2 overexpression is associated with poor prognosis in patients with glioma.
Zhang Y; Yu X; Chen L; Zhang Z; Feng S
Oncotarget; 2017 Jan; 8(1):565-573. PubMed ID: 27880940
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic implications of TERT promoter mutation status in diffuse gliomas in a routine clinical setting.
Hewer E; Prebil N; Berezowska S; Gutt-Will M; Schucht P; Dettmer MS; Vassella E
Virchows Arch; 2017 Nov; 471(5):641-649. PubMed ID: 28823044
[TBL] [Abstract][Full Text] [Related]
14. Effects of Coexistent BRAF
Moon S; Song YS; Kim YA; Lim JA; Cho SW; Moon JH; Hahn S; Park DJ; Park YJ
Thyroid; 2017 May; 27(5):651-660. PubMed ID: 28181854
[TBL] [Abstract][Full Text] [Related]
15. Association of human telomerase reverse transcriptase promoter mutation with unfavorable prognosis in glioma: A systematic review and meta-analysis.
Hua R; Li Q; Gao H; Wang B; He C; Wang Y; Zhang S; Gao L; Shang H; Wang W; Xu J
J Res Med Sci; 2023; 28():47. PubMed ID: 37496645
[TBL] [Abstract][Full Text] [Related]
16. When the Ends Are Really the Beginnings: Targeting Telomerase for Treatment of GBM.
Bollam SR; Berens ME; Dhruv HD
Curr Neurol Neurosci Rep; 2018 Mar; 18(4):15. PubMed ID: 29525892
[TBL] [Abstract][Full Text] [Related]
17. The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism.
Batista R; Cruvinel-Carloni A; Vinagre J; Peixoto J; Catarino TA; Campanella NC; Menezes W; Becker AP; de Almeida GC; Matsushita MM; Clara C; Neder L; Viana-Pereira M; Honavar M; Castro L; Lopes JM; Carvalho B; Vaz RM; Máximo V; Soares P; Sobrinho-Simões M; Reis RM; Lima J
Int J Cancer; 2016 Jul; 139(2):414-23. PubMed ID: 26914704
[TBL] [Abstract][Full Text] [Related]
18. Relationships between PTEN gene mutations and prognosis in glioma: a meta-analysis.
Xiao WZ; Han DH; Wang F; Wang YQ; Zhu YH; Wu YF; Liu NT; Sun JY
Tumour Biol; 2014 Jul; 35(7):6687-93. PubMed ID: 24705863
[TBL] [Abstract][Full Text] [Related]
19. Subgroup characteristics of insular low-grade glioma based on clinical and molecular analysis of 42 cases.
Tang C; Zhang ZY; Chen LC; Sun Z; Zhang Y; Qin Z; Yao Y; Zhou LF
J Neurooncol; 2016 Feb; 126(3):499-507. PubMed ID: 26586262
[TBL] [Abstract][Full Text] [Related]
20. Loss of Heterozygosity of 9p Is Associated with Poorer Survival in Patients with Gliomas.
Huang T; Li S; Yang Z; Liu J; Han Y
Mol Neurobiol; 2016 Nov; 53(9):6407-6412. PubMed ID: 26582467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
